Maleato de mepiramine como tratamiento de la urticaria en caballos; un estudio multicentrico, aleatorizado y controlado con placebo a doble ciego.
Urticaria, a common dermatological disorder , occur in horses (Equus caballus) of all ages [8, 13]. Although the pathophysiological mechanisms of urticaria is not very well defined in horses , it is characterized by dermal edema, with or without accompanying perivascular to diffuse infiltration including eosinophil and lymphocyte [12, 15], resulting from the mast cell degranulation and inflammation of the chemical mediators . Urticaria may have immunological and nonimmunological background . Urticaria has been suggested to be a cutaneous reaction  as a result of multivariable causes; mimicking reports in humanbeing [1, 17], such as immunological basis involving hypersensitivity, allergic urticaria (ie. insect bite, drug eruption, atopy and food allergy) [5-8, 15]. Nonimmunlogical causes include cold urticaria, exercise induced urticaria and dematographism (ie. pressure urticaria) .
Clinical appearance of equine urticaria presents as wheals, with acute to peracute onset, developing within minutes to hours , distributed bilateral and symmetrical on the trunk, neck, thorax, abdomen and extremities [8, 15]. Other rare clinical signs involve papule, giant (up to 20-40 cm diametered) or exudative wheals and gyrate/polycyclic forms [8, 15].
Clinical management of urticaria involves food elimination, intradermal skin testing and if necessary, subsequent hyposensitization therapy, and administration of corticosteroids and antihistamines. Another important point of clinical management is environmental modifications, for example, moving the horse to another location, eliminating sources of molds, removing stagnant water and stabling the horse in times when insects are known to be feeding. To the present author's knowledge, intradermal testing has not been commonly used in equine practice in Turkey. Corticosteroid treatment (i.e. prednisolone and dexamethasone) is commonly effective for controlling urticaria occuring as a result of atopy, indeed they may cause serious side effects such as laminitis, steroid induced hepatopathy and iatrogenic hyperadrenocorticism [4, 14].
Antihistamines such as hydroxizine pamoate and doxepin hydrochloride may be used in horses with urticaria . However hydroxizine and doxepin, may both cause side effects as drowsiness and nervousness in horses , resulting with challenging owner compliance. Therefore, a safely used and reasonably priced antihistamine that could be used for releiving urticaria would be of significant benefit to increase owner compliance.
The first-generation antihistamines are commonly prescribed drugs relieving allergic reactions and urticaria. Mepyramine is a first generation antihistamine, blocking the peripheral histamine H(1) receptor . It has been reported to cure photosensitization in lambs (Ovis aries) , acute respiratory distress in cows (60s taurus)  and to prevent nausea and vomitting induced by xylazine in dogs (Canis lupus familiaris) . It is commercially available in Turkey in the veterinary market. The purpose of this study was to evaluate the efficacy of mepyramine maleate for the treatment of equine urticaria in a multi-centered, randomized, placebo controlled, double blinded clinical trial.
MATERIAL AND METHODS
Multicentered, randomized, placebo-controlled, double-blinded clinical trial.
A total of 31 horses with history of conventional urticaria confined to different body parts were enrolled in the present study. The horses ranged in age from 1 to 11 years. There were 17 mares, 8 stallions and 6 geldings. Breeds represented included: 6 Thoroughbred, 5 Arabian, 5 Akhal Teke, 4 Dutch Warmblood, 4 Ponies, 3 Holsteiner and 1 of each of the following breeds: Selle Francais, Belgian Warmblood, Fresien and unknown breed.
Allocation to treatment and owners' evaluation
Horses were randomized by coin toss, in that the side of the coin (heads=control, tails= treatment) determined the assignment of each horse. Once enrolled, horses were randomly allocated into two groups. Both owners and the investigator were blinded regarding the allocation to groups. One group, consisting of 17 horses, received intramuscular mepyramine maleate * administration at a dosage of 2mg/kg twice at 12 hours intervals, while the other group, consisting 14 horses, received the placebo containing purified water (at equivalent doses of mepyramine maleate).
Investigator's evaluation of clinical lesions
At the beginning and at the end of the trial (hours 0, 6, 12, 18 and 24) clinical lesions were scored by the same investigator using a scale from 0 to 3 (0 being absent, 3 being severe) (TABLE I). The used scoring system was consistently applied to all the test subjects. Clinical lesions subject to evaluation included alopecia, scaling and crusting. Areas Evaluated included head, neck, shoulder, thorax, ventral abdomen and/or whole body. The total score of each horse was the sum of the scores assigned to each clinical signs. Therefore the total score for each horse was derived from the sum of the scores of alopecia, scaling and crusting and each horse was assessed on the same lesion on every examination. Briefly the scores were averaged for each horse [i.e. if a horse had 2 areas evaluated on the nearside and only 1 on the off side, these were added and divided by 3 (2+1)] to give the horse its score for that days examination. Mean and standard deviations of score lesions regarding the mepyramine maleate group and the placebo was shown (FIG. 1). The lesion scoring was carried out by an investigator blinded to the treatment the horses had received. The signs of resolution and therefore the improvement in clinical signs associated with urticaria were scored by the same investigator. In addition througout the study, all horses were checked daily for evidence of adverse reactions to treatment. Besides clinical follow-up was further carried out for 1 months for evaluation of possible recurrence.
Clinical recovery was deemed the resolution of dermatologic changes related to urticaria. Cure was defined when all clinico-dermatological lesions were resolved.
Differences in the clinical score between the treatment group and the untreated placebo control group on the examination days were assessed by Mann-Whitney U test. Differences in the clinical score changes within-subject factor of time were analyzed using Wilcoxon test .
[FIGURE 1 OMITTED]
RESULTS AND DISCUSSION
Clinical signs and culture results
Among 31 horses examined, all had clinical lesions of urticaria. Accompanying skin lesions of urticarial horses were variable (TABLE II). They often exhibited conventional forms of urticaria (24/31), and in addition giant/exudative (4/31) or polycyclic (gyrate) forms of wheals (3/31) (FIG. 2) were observed. Other less common signs included scales (14/31), crusts (9/31), papules (8/31) (FIG. 4), alopecia (12/31) and oozing (4/31). The thorax (8/31), neck (7/31), and extremities (5/31) were most commonly involved. All affected animals had normal temperature, pulse and respiration. Other body systems were also normal.
In all of the horses treated, the lesions improved gradually within 6 hours after treatment. Complete clinical remission was detected within 6 to 18 hours and all treated horses completely cured within 24 hours of starting treatment (FIGS. 3 and 5). Urticaria was stil evident in 8 out of 14 untreated control horses throughout the study. No recurrency was observed in treated horses within 1 week after therapy. No adverse post-treatment reaction was observed in any of the treated animals. Further follow-up was available for 1 months duration, with no recurrency.
Investigator's clinical scores (FIG. 1)
As a function of time, mepyramine maleate treated group showed significant improvement in scores from hour 6 to hours 24, while the placebo group showed weak changes in scores. Comparison of the two groups revealed that the clinical scores did not differ between the groups on hour 0, whereas the treatment group showed a significantly lower clinical score than placebo group on from hour 6 and 12 (P<0.05) to hours 18 and 24 (P<0.001).
In this study, mepyramine maleate treatment was found to be effective in decreasing investigator's clinical scores in horses with urticaria. The beneficial effect of the drug in this study was succesfull management of urticaria. In an attempt to mimic clinical practice, clinical evaluations including scoring was the main outcome measure considered in this clinical trial. The scoring system used in this study had not been previously validated, as to the present authors knowledge, because there are lack of clinical trials regarding scoring system in horses with urticaria. This scoring system, however, was purposely designed to show both extent and severity of the disease and to monitor therapy. Comparison of the two groups revealed that the clinical scores did not differ between the groups on hour 0, while the treatment group showed a significantly lower clinical score than placebo group on hours 6 and 12 (P<0.05) to hours 18 and 24 (P<0.001).
[FIGURE 2 OMITTED]
[FIGURE 3 OMITTED]
[FIGURE 4 OMITTED]
[FIGURE 5 OMITTED]
Treatment with mepyramine maleate resulted in a statistically significant cure on urticaria affected horses and the clinical signs resolved in every case treated. On the basis of clinical examinations, mepyramine maleate was not associated with any adverse effect. Further studies with larger numbers of horses control groups are required. It should be mentioned that urticarial diseases show minor unsignificant clinical signs to systemic life-threatening condition, therefore if the underlying condition is not defined and a definitive diagnosis can not be warranted, mepyramine maleate should be the choice of medication, at least in an attempt to manage the clinical signs.
Recibido: 26 / 06 / 2009. Aceptado: 05 / 04 / 2010.
 BLAUVELT, A.; HWANG, S.T.; UDEY, M.C. II. Allergic and immunologic diseases of the skin. J Allergy Clin Immun. 111: 560-70. 2003.
 BORKU, MK; OZKANLAR, Y; HANEDAN, B; URAL, K. Antihistaminic administration to prevent nausea and vomiting induced by xylazine in dogs. Vet Fak Derg Uludag Univ. 24(1/4): 99-104. 2005.
 CLAUSEN, H.H.; SCHOON, H.A. Acute respiratory distress syndrome in adult cattle (Asthma syndrome) Tier aerztl Umschau. 45(7):457-462. 1990.
 COHEN, N.D.; CARTER, G.K. Steroid hepatopathy in a horse with glucocorticoid-induced hyperadrenocorticism. JAVMA. 200:1682-1684. 1992.
 EVANS, A.G.; PARADIS, M.R.; O'CALLAGHAN, M. Intradermal testing of horses with chronic obstructive pulmonary disease and recurrent urticaria. Am J Vet Res. 53: 203-208. 1992.
 FADOK, V.A. Overview of equine papular and nodular dermatoses. Vet Clinics North Am: Equine Pract. 11: 61-74. 1995.
 FRANCQUEVILLE, M.; SABBAH, A. Chronic urticaria in sports horses. Rev Fr Allergol. 31: 212-13. 1999.
 JOSE-CUNILLERAS, E.; KOHN, C.W.; HILLIER, A.; SAVILLE, W.J.; LORCH, G. Intradermal testing in healthy horses and horses with chronic obstructive pulmonary disease, recurrent urticaria, or allergic dermatitis. JAVMA. 219: 1115-1121. 2001.
 LIU, B.; ZHANG, X.; WANG, C.; ZHANG, G.; ZHANG, H. Antihistamine mepyramine directly inhibits KCNQ/M channel and depolarizes rat superior cervical ganglion neurons. Neuropharmacol. 54:629-639. 2008.
 OZDAMAR, K.; SPSS ile Biyoistatistik. Kaan Kitabevi. Eskisehir. 2003.
 RUFENACHT, S.; MARTI, E.; VON TSCHARNER, C.; DOHERR, M.G.; FORSTER, U.; WELLE, M.; ROOSJE, P.J. Immunoglobulin E-bearing cells and mast cells in skin biopsies of horses with urticaria. Vet Dermatol. 16 (2): 94-101. 2005.
 SCHEIE, E.; FLAOYEN, A. Autumn photosensitization (alveld) in lambs. Norsk Veterinaertidsskrift. 115(10): 651-653. 2003.
 SCOTT, DW; MILLER, WH. Skin immune system and allergic skin diseases. Urticaria and angioedema. Equine Dermatology. St. Louis, MO, W.B. Saunders. 422-427 pp. 2003.
 VANDENABEELE, S.I.J.; WHITE, S.D.; AFFOLTER, V.K.; KASS, P.H.; IHRKE, P.J. Pemphigus foliaceus in the horse: a retrospective study of 20 cases. Vet Dermatol. 15:381-388. 2004.
 VON TSCHARNER, C.; KUNKLE, G.; YAGER, J. Immunologic diseases. Vet Dermatol. 11: 163-78. 2000.
 WHITE, S.D. Advances in Equine Atopic Dermatitis, Serologic and Intradermal Allergy Testing. Clin Tech Equine Pract. 4(4):311-313. 2005.
 ZUBERBIER, T. Urticaria. Allergy. 58: 1224-34. 2003.
Kerem Ural and Buient Ulutas
Department of Internal Medicine, Faculty of Veterinary, University of Adnan Menderes, Aydin-Turkey.
* Histavet inj. flk., Vetas[R], Turkey.
TABLE I ON HOURS 0, 6, 12 AND 24 HORSES WERE GIVEN A CLINICAL SCORE AND THE SEVERITY OF URTICARIA WAS GRADED AS: OF (ABSENT = 0, MILD = 1, MODERATE = 2, SEVERE = 3) ACCORDING TO THE SEVERITY TYPES. THE SIGNS OF RESOLUTION AND THEREFORE THE DISAPPEARENCE OF URTICARIA WERE SCORED BY THE INVESTIGATOR BLINDED TO THE TREATMENT THE HORSES HAD RECEIVED. THE CASES WERE RANDOMLY ASSIGNED TO EITHER MEPYRAMINE MALEATE TREATMENT GROUP (N = 17) ORA PLACEBO (N = 14)./ EN LAS HORAS 0; 6; 12 Y 24 CABALLOS SE LES DIO UNA PUNTUACION CLINICA Y LA SEVERIDAD DE LA URTICARIA SE CLASIFICA COMO: DE (AUSENTE = 0, LEVE = 1, MODERADA = 2, SEVERO = 3) SEGUN EL TIPO DE GRAVEDAD. LOS SIGNOS DE LA RESOLUCION Y POR LO TANTO LA DESAPARICION DE LA URTICARIA FUERON ANOTADOS POR EL INVESTIGADOR CIEGO PARA EL TRATAMIENTO QUE LOS CABALLOS HABIAN RECIBIDO. LOS CASOS FUERON ASIGNADOS AL AZAR A CUALQUIER GRUPO DE TRATAMIENTO CON MALEATO DE MEPIRAMINA (N = 17) O UN PLACEBO (N = 14). Hour 0 Hour 6 Groups Score 3 2 1 0 3 2 1 0 Treatment (n = 17) 11 3 3 0 4 3 3 7 Placebo control (n = 14) 9 2 3 0 7 3 3 1 Day 12 Day 18 Groups Score 3 2 1 0 3 2 1 0 Treatment (n = 17) 1 2 4 10 0 1 1 15 Placebo control (n = 14) 5 3 3 3 6 2 2 4 Hour 24 Groups Score 3 2 1 0 Treatment (n = 17) 0 0 0 17 Placebo control (n = 14) 4 2 2 6 TABLE II CLINICAL BACKGROUND FOR HORSES WITH URTICARIA. N, NUMBER OF HORSES WITH THE CLINICAL SIGNS COMPARED TO THE TOTAL NUMBER OF HORSES/LOS ANTECEDENTES CLINICOS PARA LOS CABALLOS CON URTICARIA. N, EL NUMERO DE CABALLOS CON LOS SIGNOS CLINICOS EN COMPARACION CON EL NUMERO TOTAL DE CABALLOS. Duration of Sign N % clinical signs N % Wheals 31/31 100 < 1 week 11/31 35 -conventional 24/31 77 -giant/exudative 4/31 12 -polycyclic (gyrate) 3/31 9 Scales 14/31 45 >4 weeks 9/31 29 Crusts 9/31 29 recurring 4/31 12 Papules 8/31 25 >4 weeks 5/31 16 Alopecia 12/31 38 >4 weeks 7/31 22 Oozing 4/31 12 1-4 weeks 3/31 9 Localization Sign of lesions N % Wheals Whole body 3/31 9 -conventional Head 3/31 9 -giant/exudative Neck 7/31 22 -polycyclic (gyrate) Shoulder 3/31 9 Scales Extremities 5/31 16 Crusts Thorax 8/31 25 Papules Abdomen 2/31 6 Alopecia Oozing
|Printer friendly Cite/link Email Feedback|
|Author:||Ural, Kerem; Ulutas, Bulent|
|Publication:||Revista Cientifica de la Facultad de Ciencias Veterinarias|
|Date:||Sep 1, 2010|
|Previous Article:||Estabilidad enzootica de babesiosis bovina en la region de Puerto Berrio, Colombia.|
|Next Article:||Patogenos contagiosos y ambientales aislados de cuartos mamarios con mastitis subclinica de alto riesgo en tres fincas del estado Zulia.|